Glax­o­SmithK­line, Vir look to suc­ceed where Lil­ly failed with NIH an­ti­body study in hos­pi­tal­ized Covid-19 pa­tients

In the hunt for an ef­fec­tive Covid-19 ther­a­py, mon­o­clon­al an­ti­bod­ies have turned up mixed da­ta so far. Eli Lil­ly was Ex­hib­it A in Oc­to­ber when the NIH quick­ly cut its an­ti­body from a tri­al in mod­er­ate­ly ill hos­pi­tal­ized pa­tients. But now, Glax­o­SmithK­line and part­ner Vir Biotech­nol­o­gy are hop­ing to suc­ceed where Lil­ly failed.

Af­ter Lil­ly’s sting­ing loss in achiev­ing sus­tained re­cov­ery in hos­pi­tal­ized Covid-19 pa­tients treat­ed with its an­ti­body, Glax­o­SmithK­line and Vir will now take a shot at that pop­u­la­tion as part of a place­bo-con­trolled sub­tri­al in the NIH’s “mas­ter pro­to­col” Ac­tiv-3.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER